R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 70.01
-0.63 (-0.89%)
Jan 22, 2026, 4:00 PM EST
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 6.66 billion as of January 22, 2026. Its market cap has increased by 41.15% in one year.
Market Cap
6.66B
Enterprise Value
4.96B
Revenue
789.45M
Ranking
n/a
PE Ratio
43.99
Stock Price
70.01
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 6.66B, an increase of 23.33%. That is a compound annual growth rate of 6.22%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 22, 2026 | 6.66B | 17.57% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GemPharmatech | 7.54B |
| Suzhou Fengbei Biotech Stock | 7.09B |
| Beijing Konruns Pharmaceutical | 6.77B |
| Xiangxue Pharmaceutical | 6.67B |
| Kexing Biopharm | 6.66B |
| Jiangsu Bioperfectus Technologies | 6.66B |
| Shanghai OPM Biosciences | 6.48B |
| PharmaResources (Shanghai) | 6.38B |